CIPLA News Today

Cipla Ltd Share Price

CIPLA

CMP as on 18-Apr-24 12:00
₹ 1,347

icon -27.90 | -2.03%

Open
₹ 1,376
Turnover(lac)
₹ 40,071
Prev. Close
₹ 1,375.20
Day's Vol (shares)
₹ 2,974,196
Day's Vol (shares)
₹ 1,342.40         ₹ 1,383.65

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
Image not found

Cipla Buys Ivia Beaute's Beauty Brands for Rs 130 Crore

The deal is anticipated to close within 60 days after the BTA's signature, or on a later date that the parties have mutually agreed upon in writing.

  • 16 Apr, 2024 |
  • 11:04 AM
Image not found

Q3FY24 Review: Cipla: Advair/Abraxane delay partly offset by Peptides

Recommendation: Add; Target price: Rs 1345

  • 29 Jan, 2024 |
  • 12:29 PM
Image not found

Cipla’s Samina Hamied quits as executive vice chairperson due to personal commitments

The corporation claimed "personal and family commitments" as the reason for her departure from her present post.

  • 29 Jan, 2024 |
  • 12:23 PM
Image not found

Cipla reports 32% y-o-y growth in net profit to Rs 1,056 crore; stock climbs to new 52-week

Its sales for the quarter increased 13.7% YoY to Rs 6,604 crore

  • 23 Jan, 2024 |
  • 10:11 AM
Image not found

Cipla-led arm recalls one lot of Vigabatrin owing to seal intergrity issue

An improper pouch seal may cause powder mix to leak outside the pouch

  • 11 Dec, 2023 |
  • 11:41 AM
Image not found

Cipla Stock Dips 7% as USFDA Issues Warning Letter Over GMP Inspection Issues

The warning letter, received on November 18, pertains to routine GMP inspection at Cipla's Pithampur facility conducted on February 6 and 7, 2023.

  • 23 Nov, 2023 |
  • 1:26 PM
Image not found

The USFDA has warned Cipla about its manufacturing processes at its Pithampur factory

This warning letter outlines infractions pertaining to procedures or controls used at the facility that do not follow the specified cGMP rules and offers instructions for making the required corrections.

  • 20 Nov, 2023 |
  • 12:29 PM
Image not found

Q2FY24 Review: Cipla: Robust US pipeline, but valuations full

Recommendation: Add; Target price: Rs 1200

  • 30 Oct, 2023 |
  • 1:47 PM
Image not found

Cipla Q2 Results: Revenue increases by 15% as profit soars 43% YoY at Rs 1,131 crore

Its sales are above the market expectation of Rs 6,523 crore by 14.57% YoY to Rs 6,678.15 crore, marking the company's greatest quarterly topline ever.

  • 30 Oct, 2023 |
  • 10:19 AM
Image not found

Q2FY24 Preview: Cipla: Revenue seen at Rs. 64,229 million, PAT at Rs. 9,389 million

Subuded performance likely during the quarter.

  • 26 Oct, 2023 |
  • 11:12 AM